A Review of Research on CRISPR/Cas9 Gene Editing Technology in Disease Treatment

The appearance of CRISPR/Cas9 gene editing technology marks a revolutionary advance in the field of gene editing. With its high degree of specificity and efficiency, this technology enables precise modification of genome-specific loci. This paper reviews the mechanism of CRISPR/Cas9 and its applications in various fields such as genetic disease treatment, cancer therapy, antiviral therapy, gene function research and virus detection. Also, the challenges of off-target effects are discussed and strategies to minimize them are proposed, The purpose of this study is to propose applications and innovations of CRISPR/Cas9 technology in medical therapeutics while addressing its current limitations.

• Publication year

  2024

• Venue

  Academic Journal of Science and Technology

• Publication date

  2024-12-26

• Fields of study

  Not labeled

• Identifiers
  DOI 10.54097/5crj2x50
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

  2022cited by this paper
• In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels

  2021cited by this paper
• Point-of-care testing for COVID-19 using SHERLOCK diagnostics

  2020cited by this paper
• CRISPR-Cas9 for cancer therapy: Opportunities and challenges.

  2019cited by this paper
• Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy

  2019cited by this paper
• Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6

  2018cited by this paper
• In vivo gene editing in dystrophic mouse muscle and muscle stem cells

  2016cited by this paper
• CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

  2016cited by this paper
• Advances in therapeutic CRISPR/Cas9 genome editing.

  2016cited by this paper
• Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9

  2015cited by this paper
• Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus

  2013cited by this paper
• Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

  1992cited by this paper

• No citing papers are available for this paper.